Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) EBITDA (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed EBITDA for 11 consecutive years, with -$27.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 21.4% to -$27.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$119.3 million through Dec 2025, down 82.5% year-over-year, with the annual reading at -$119.3 million for FY2025, 82.5% down from the prior year.
  • EBITDA hit -$27.4 million in Q4 2025 for Voyager Therapeutics, up from -$27.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $124.1 million in Q1 2023 to a low of -$34.9 million in Q4 2024.
  • Historically, EBITDA has averaged -$8.5 million across 5 years, with a median of -$21.9 million in 2021.
  • Biggest five-year swings in EBITDA: plummeted 512.49% in 2022 and later surged 679.94% in 2023.
  • Year by year, EBITDA stood at $5.7 million in 2021, then tumbled by 512.49% to -$23.5 million in 2022, then soared by 340.75% to $56.6 million in 2023, then tumbled by 161.6% to -$34.9 million in 2024, then rose by 21.4% to -$27.4 million in 2025.
  • Business Quant data shows EBITDA for VYGR at -$27.4 million in Q4 2025, -$27.7 million in Q3 2025, and -$33.4 million in Q2 2025.